IL1B and type 2 diabetes mellitus: Protein-based therapies that block the action of IL-1β, one of its downstream products, have shown promising outcomes in patients with gout, CAPS, and type 2 diabetes in clinical trials [9,66,67], suggesting that inhibition of the NLRP3 inflammasome is likely the right path to curb NLRP3 inflammasome-mediated diseases.